Mihaela Obreja

1.4k total citations
24 papers, 970 citations indexed

About

Mihaela Obreja is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Mihaela Obreja has authored 24 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 10 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Mihaela Obreja's work include Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (9 papers) and Bipolar Disorder and Treatment (6 papers). Mihaela Obreja is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (9 papers) and Bipolar Disorder and Treatment (6 papers). Mihaela Obreja collaborates with scholars based in United States, France and Spain. Mihaela Obreja's co-authors include Kelly Monk, David Axelson, David A. Brent, David J. Kupfer, Benjamin I. Goldstein, Satish Iyengar, Mary Beth Hickey, Boris Birmaher, Wael Shamseddeen and Catherine Kalas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Psychiatry.

In The Last Decade

Mihaela Obreja

23 papers receiving 952 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mihaela Obreja United States 15 450 372 340 309 207 24 970
Satish Valluri United States 13 188 0.4× 137 0.4× 94 0.3× 143 0.5× 158 0.8× 37 644
Charles Cunningham Canada 17 436 1.0× 27 0.1× 196 0.6× 298 1.0× 203 1.0× 31 1.1k
Catherine Doyen France 10 129 0.3× 437 1.2× 360 1.1× 184 0.6× 287 1.4× 32 743
David Rintell United States 14 114 0.3× 54 0.1× 42 0.1× 85 0.3× 55 0.3× 23 633
Mary Rensel United States 14 52 0.1× 122 0.3× 88 0.3× 39 0.1× 81 0.4× 43 855
Shuichi Ozono Japan 15 28 0.1× 57 0.2× 33 0.1× 144 0.5× 50 0.2× 44 618
J. Parkes United Kingdom 10 248 0.6× 30 0.1× 40 0.1× 221 0.7× 18 0.1× 14 460
Federica Ricci Italy 12 77 0.2× 14 0.0× 111 0.3× 162 0.5× 40 0.2× 51 522
Elizabeth Smibert Australia 12 38 0.1× 26 0.1× 99 0.3× 32 0.1× 48 0.2× 18 679
Elizabeth Wise United States 12 140 0.3× 45 0.1× 69 0.2× 38 0.1× 61 0.3× 26 415

Countries citing papers authored by Mihaela Obreja

Since Specialization
Citations

This map shows the geographic impact of Mihaela Obreja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mihaela Obreja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mihaela Obreja more than expected).

Fields of papers citing papers by Mihaela Obreja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mihaela Obreja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mihaela Obreja. The network helps show where Mihaela Obreja may publish in the future.

Co-authorship network of co-authors of Mihaela Obreja

This figure shows the co-authorship network connecting the top 25 collaborators of Mihaela Obreja. A scholar is included among the top collaborators of Mihaela Obreja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mihaela Obreja. Mihaela Obreja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burke, Michael J., David S. Ziegler, Francisco Bautista, et al.. (2021). Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 138(Supplement 1). 1235–1235. 1 indexed citations
2.
3.
4.
Façon, Thierry, Rubén Niesvizky, María‐Victoria Mateos, et al.. (2020). Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Advances. 4(21). 5449–5459. 26 indexed citations
5.
Ghobrial, Irene M., Ravi Vij, David S. Siegel, et al.. (2019). A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clinical Cancer Research. 25(16). 4907–4916. 39 indexed citations
6.
Burke, Michael J., David S. Ziegler, Francisco Bautista, et al.. (2019). Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 134(Supplement_1). 3873–3873. 8 indexed citations
7.
Façon, Thierry, Rubén Niesvizky, Katja Weisel, et al.. (2019). Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR.. Journal of Clinical Oncology. 37(15_suppl). 8028–8028. 3 indexed citations
8.
9.
Siegel, David S., Meletios Α. Dimopoulos, Heinz Ludwig, et al.. (2018). Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology. 36(8). 728–734. 183 indexed citations
10.
Mateos, María‐Victoria, Hartmut Goldschmidt, Jesús F. San Miguel, et al.. (2018). Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematological Oncology. 36(2). 463–470. 14 indexed citations
11.
Hari, Parameswaran, MV Mateos, Rafat Abonour, et al.. (2017). Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 31(12). 2630–2641. 16 indexed citations
12.
Siegel, David S., Albert Oriol, Péter Rajnics, et al.. (2017). Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 17(1). e142–e142. 5 indexed citations
13.
Badin, Firas, Anne C. Chiang, William B. Fisher, et al.. (2016). Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.. Journal of Clinical Oncology. 34(15_suppl). e20092–e20092. 2 indexed citations
14.
Ghobrial, Irene M., Michael R. Savona, Ravi Vij, et al.. (2016). Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies. Blood. 128(22). 2110–2110. 20 indexed citations
15.
Goldstein, Tina R., Benjamin I. Goldstein, Mihaela Obreja, et al.. (2012). Is bipolar disorder specifically associated with aggression?. Bipolar Disorders. 14(3). 283–290. 65 indexed citations
16.
Goldstein, Tina R., Mihaela Obreja, Wael Shamseddeen, et al.. (2011). Risk for Suicidal Ideation Among the Offspring of Bipolar Parents: Results From the Bipolar Offspring Study (BIOS). Archives of Suicide Research. 15(3). 207–222. 17 indexed citations
17.
Diler, Rasim Somer, Boris Birmaher, David Axelson, et al.. (2011). Dimensional psychopathology in offspring of parents with bipolar disorder. Bipolar Disorders. 13(7-8). 670–678. 31 indexed citations
18.
Bella, Tolulope, Tina R. Goldstein, David Axelson, et al.. (2011). Psychosocial functioning in offspring of parents with bipolar disorder. Journal of Affective Disorders. 133(1-2). 204–211. 39 indexed citations
19.
Birmaher, Boris, David Axelson, Benjamin I. Goldstein, et al.. (2010). Psychiatric Disorders in Preschool Offspring of Parents With Bipolar Disorder: The Pittsburgh Bipolar Offspring Study (BIOS). American Journal of Psychiatry. 167(3). 321–330. 114 indexed citations
20.
Birmaher, Boris, David Axelson, Kelly Monk, et al.. (2009). Lifetime Psychiatric Disorders in School-aged Offspring of Parents With Bipolar Disorder. Archives of General Psychiatry. 66(3). 287–287. 281 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Satish Valluri Breakdown of academic impact, for papers by Charles Cunningham Breakdown of academic impact, for papers by Catherine Doyen Breakdown of academic impact, for papers by David Rintell Breakdown of academic impact, for papers by Mary Rensel Breakdown of academic impact, for papers by Shuichi Ozono Breakdown of academic impact, for papers by J. Parkes Breakdown of academic impact, for papers by Federica Ricci Breakdown of academic impact, for papers by Elizabeth Smibert Breakdown of academic impact, for papers by Elizabeth Wise
Rankless by CCL
2026